Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Piramal Healthcare Gets European Approval For Regenerative Medicine

Piramal Healthcare Ltd. announced that it had received the European regulatory approval to sell BST-CarGel, a product that helps repair tissue damage caused by osteoarthritis or sports injuries.

This approval enables the company to start selling BST-CarGel in all European Union countries. Furthermore, it will serve as the basis to obtain commercial authorization for the product in other geographic areas of the world such as Middle East, the Asia Pacific region, South America and other countries including India.

The company plans to launch the product in the October-December quarter

In 2010, Piramal Healthcare acquired Montreal, Canada-based medical device company BioSynech Technologies, Inc. for C$3.9 million, which gave it access to the Canadian company's portfolio of biotherapeutic thermogels, including BST-CarGel.

BST-CarGel, a EU class III medical device, is a novel natural polysaccharide based liquid scaffold which, combined with the patient's whole blood, is then implanted into a debrided cartilage lesion prepared with bone marrow access. As demonstrated in a controlled clinical trial, this procedure results in a superior cartilage repair volume and quality compared to the standard o care treatment with the goal of offering a more durable longer term treatment.

Piramal Healthcare Chairman Ajay Piramal said, "BST-CarGel provides us with a superior way to address significant unmet medical needs in the global knee cartilage repair market. The current European approval provides access to a $200 million market in Europe with the potential for a larger market with greater penetration of treatment in Europe. As we obtain commercial approval in other geographic areas, this will give us access to additional markets."

At the BSE, Piramal Healthcare shares are currently trading at Rs.460.75, up 0.69 percent from the previous close.

Register
To receive FREE breaking news email alerts for Piramal Healthcare Ltd. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Beverages giant Coca-Cola Co. reported Tuesday a profit for the third quarter that decreased 14 percent from last year, despite higher worldwide volumes, reflecting a revenue drop. Adjusted earnings per share matched analysts' expectations, even as quarterly revenues missed their estimates. Following the announcement, the company's shares are trading more than five percent lower in early deals. Apple Inc. said Monday that its fourth quarter profit rose 13% from last year, driven by strong sales of its iPhones and Mac computers. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly sales. At the same time, the company gave an upbeat revenue forecast for the current quarter, which includes the all important holiday season. Programmable chipmaker Xilinx Inc. (XLNX) said Thursday after the markets closed that its second quarter profit rose 21% from last year, helped by higher revenue and better cost control. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue....
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.